The House budget hearing on Thursday turned tense as Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. clashed with Democratic members. They accused him of misrepresenting changes in vaccine monitoring, while he countered by suggesting that their positions were influenced by pharmaceutical donations.
Kennedy was present before the House Energy and Commerce Health Subcommittee to discuss the Trump administration’s 2026 budget proposal.
Throughout the hearing, Kennedy maintained an aggressive tone. He seemed to promise transparency regarding the agency’s structural changes but denied any conflict of interest accusations related to funding.
Key moments from the hearing included:
Response to Palone’s Claims
Kennedy reacted defensively when Rep. Frank Pallone Jr. (D-N.J.) challenged his commitment to “radical transparency” following changes in vaccine monitoring practices. Pallone pointed out HHS’s inadequate response to Congress and the recent dismissal of the entire Advisory Committee on Immunization Practices (ACIP) as failures of transparency.
“What are you afraid of?” Pallone pressed. “Are you afraid of public comments on proposals that seem to contradict most scientific views?”
Kennedy, who had previously struggled to find time to respond to questions, used his opportunity to address Pallone’s past support for vaccine injury claims, emphasizing Pallone’s connections to pharmaceutical donations. “You’ve received more than $2 million from Big Pharma compared to anyone else here,” Kennedy claimed.
Rep. Diana Degette (D-Colo.) quickly interjected, declaring that Kennedy was “implicating Mr. Pallone.” Subcommittee Chair Buddy Carter (R-Ga.) called for a pause, leading to Kennedy retracting his comments about Pallone.
“You Misled Senator Cassidy”
Rep. Kim Schlieu (D-Wash.) accused Kennedy of misleading Sen. Bill Cassidy (R-La.) during prior confirmations. Cassidy expressed initial hesitation regarding Kennedy’s nomination but noted he had received commitments from Kennedy about maintaining the ACIP structure—a promise he felt was broken when Kennedy dismissed the committee’s members.
The senator criticized the lack of qualified experience among the new appointees, questioning Kennedy’s credibility. “Senator Cassidy seems to trust you less on vaccinations,” Schlieu noted, reiterating the sentiment that Kennedy had not been truthful.
Kennedy denied any misleading intent, insisting he hadn’t broken any commitments, but Cassidy’s office later clarified that their concerns revolved around the process, not staffing.
Knowledge of Spending Cuts
Kennedy appeared unaware of the “protect spending” initiative from the Department of Government Efficiency (DOGE), which aims to eliminate grants that conflict with the Trump administration’s agenda. This measure has led to significant cuts to various agencies, causing frustration among stakeholders.
Degette referenced previous correspondence in which she requested information about this initiative but received no reply. “Did you conduct a cost-benefit analysis?” she pressed. Kennedy repeatedly claimed ignorance of the situation.
HIV Vaccine Research Funding
Rep. Troy Carter (D-La.) questioned Kennedy about cuts to HIV prevention research funding, expressing confusion over recent resource reallocations at the CDC. Carter emphasized that a staggering 91% of federal funds for HIV prevention come from the HHS, contrasting Kennedy’s focus on organizational restructuring.
When asked about the implications of cutting such funding, Kennedy dismissed the need for the studies, while Carter countered with the real-life impact of these vital research efforts.
Conflict of Interest Concerns
Rep. Jake Auchincloss (D-Mass.) raised issues about potential conflicts of interest regarding Kennedy’s close adviser, Calley Means. Auchincloss pointed out that Means co-founded Trueemed, a company related to health savings accounts, and questioned whether this posed a conflict with Kennedy’s claims of transparency.
When engaged in a back-and-forth about financial disclosures, Kennedy challenged Auchincloss, suggesting he too had significant financial ties. Auchincloss clarified the necessity of transparency, revealing his own disclosure as a response.
The atmosphere at the hearing encapsulated the ongoing tensions surrounding public health policy, vaccines, and the influence of pharmaceutical companies, leaving many questions lingering about integrity and commitments made.
